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Abstract
Malaria remains a significant worldwide public health problem. To address biological questions, researchers rely on the exper-
imental murine model. For decades, chloroquine (CQ) and pyrimethamine (Pyr) have been used to clear Plasmodium infections
in experimental animals using standardised accepted protocols and, because of this, drug-treated controls are rarely included.
However, there is limited data available on the modulation of anti-malarial immunity, including generation of memory B cells,
when these drugs are administered days after malaria infection. We investigated B cell responses to an important malaria
glycolipid, glycosylphosphatidylinositol (GPI), and the hapten nitrophenol (NP), with or without standard CQ and Pyr treatment
using the murine model. At day 14, CQ/Pyr treatment significantly suppressed the frequency of NP+IgG1+ memory B cells in
NP-KLH-immunised mice. Furthermore, CQ/Pyr-treated NP-KLH-immunised mice did not have significantly higher cellular
counts of NP+ B cells, germinal centre B cells, nor NP+IgG1+ memory B cells than naïve mice (CQ/Pyr treated and untreated).
CQ/Pyr-treated GPI-KLH-immunised mice did not have significantly higher cellular counts of GPI+ B cells than naïve untreated
mice. By day 28, this effect appeared to resolve since all immunisedmice, whether treated or untreated, had significantly higher B
cell proliferative responses than naïve mice (CQ/Pyr treated and untreated) for the majority of B cell phenotypes. The current
study emphasises the potential for drug modulation of antigenic B cell responses when using standardised malaria treatment
protocols in the experimental murine model. It is recommended that drug-treated controls are included when using experimental
malaria infections to address biological questions.
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Introduction
Immunity to malaria is hard to acquire and easily lost (Jeffery
1966), phenomena that contribute to the global persistence of
Plasmodium. Inadequate B cell memory recall and
Plasmodium immunomodulation of host responses are likely
involved (reviewed in Frosch and John 2012). When studying
Plasmodium, well-established malaria mouse infection
models are often utilised to investigate pathogenesis,
immunomodulation, anaemia, liver-stage infections and
blood-stage infections (Helegbe et al. 2018; Lau et al. 2014;
Ryg-Cornejo et al. 2016b). To do this, administration of low
doses (10 mg/kg each) of chloroquine (CQ) and pyrimeth-
amine (Pyr) are crucial to prevent the progression of disease
and effectively clear the infection in these mice (Schofield
et al. 2017). Standard parasite clearance protocols include si-
multaneous i.p. injection of the drugs days after malaria chal-
lenge, followed by drinking water spiked with anti-malarials
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(Schofield et al. 2017). Despite the known immunomodulato-
ry effects of CQ and Pyr (Brauner et al. 2017; Khan et al.
2018; Qin et al. 2014; Rynes 1997), many studies do not
include parallel drug-treated control mice. This study was
specifically designed to observe if the standard protocols used
to clear malaria infection alter B cell responses to foreign
antigen.
Materials and methods
To assess immunomodulatory effects of anti-malarial treat-
ment on B cell activation, mice were immunised with the
important malaria glycolipid, glycosylphosphatidylinositol
(GPI) (Schofield and Hackett 1993), or the hapten nitrophenol
(NP), a commonly used antigen to study various aspects of B
cell responses (Inamine et al. 2005; Lalor et al. 1992).
Mouse immunisations
An equal number of female and male inbred C57BL/6 mice
(6–8 weeks of age) were used for all experiments and were
evenly distributed in different groups. All procedures com-
plied with the Walter and Eliza Hall Institute Animal Ethics
Committee requirements.
Mice were immunised withPlasmodiumGPI conjugated to
the carrier protein keyhole limpet haemocyanin (KLH), or NP
also conjugated to KLH. Briefly, synthetic GPI was conjugat-
ed to maleimide-activated KLH (ThermoFisher Scientific,
USA) using 2-iminothiolane and stored at − 80 °C until use
(GPI-KLH). 4-Hydroxy-3-nitrophenyl acetyl-Osu (NP-Osu)
(Biosearch Technologies, USA) was conjugated to KLH
(Sigma-Aldrich, USA; molar ratio between 13 and 20) accord-
ing to the manufacturer’s instructions and stored at − 20 °C
until use (NP-KLH).
For the immunisations, stock antigen vials were thawed
and diluted to 20 μg per 100 μL in Hepes Buffered Eagles
Essential Medium (HEM). An equal volume of 10% alum
(Sigma-Aldrich, USA) was added to the diluted antigen and
the pH was adjusted to 6.5 with 1 M sodium hydroxide
(NaOH). The solution was washed four times with PBS and
resuspended in PBS to 50% of the original volume. For ex-
ample, if the antigen was originally diluted to 2 mL in HEM,
then only 1 mL of PBS was added for the final resuspension.
Twenty micrograms per 100 μL of GPI-KLH or NP-KLH
precipitated on 10% alum was injected i.p. per mouse.
B cell activation was assessed in two independent experi-
ments at day 14 (prime) and day 28 (boost). Prime experi-
ments involved CQ/Pyr treating half the group of mice at
day 5 following immunisation. Mice were subsequently
euthanised at day 14. For boost experiments, mice were first
immunised at day 0 and half the group of mice were CQ/Pyr
treated as above or left untreated. At day 16, mice were
boosted with NP-KLH or GPI-KLH as above. All mice in-
cluded in this set of experiments were euthanised at day 28.
Drug treatment was an i.p. injection of CQ (10mg/kg) and Pyr
(10 mg/kg) followed by 5 days of drinking water spiked with
CQ (0.6 mg/mL) and Pyr (0.07 mg/mL). The regime was
specifically chosen to mimic standardised protocols of para-
site clearance in experimental murine models (Schofield et al.
2017). Naïve mice included as controls were either left un-
treated or administered the same drug treatment as the
immunised groups.
Phenotypic analysis of B cells was performed by flow cy-
tometry and detection of antigen-specific ASCs was per-
formed using ELISPOTs. Naïve mice were included as base-
line comparisons.
Flow cytometry
Single cell suspensions were prepared from spleens as previ-
ously described (Lee et al. 2017; Ryg-Cornejo et al. 2016a).
The following fluorochrome-conjugated monoclonal antibod-
ies were used to stain B cells: Pacific Blue (PB) anti-CD19
(clone 1D3, Ebioscience, USA), allophycocyanin (APC) anti-
IgG1 (clone X56), PECy7 anti-CD95 (clone Jo2), and fluo-
rescein isothiocyanate (FITC) anti-CD38 (clone Ab90). IgD+
and/or Gr1+ cells were determined by Alexa 680 (A680) anti-
IgD (clone 1126C) and A680 anti-Gr1 (clone 8C5). Dead cells
were excluded using live/dead fixable yellow dead cell stain-
ing kits (Life Technologies, USA). Antigen specificity was
determined using GPI-BSA-BIO/Streptavidin-PE or NP-PE.
Germina l Cent re (GC) B cel l s were def ined as
CD19+IgD−CD95+CD38lo. Within GC populations, antigen-
positive and class-switched B cells were defined as GPI/
NP+IgG1+ (CD19+IgD−CD95+CD38loGPI/NP+IgG1+). Total
activated B cells that were antigen positive and class switched
were defined as CD19+IgD−GPI/NP+IgG1+. Since the adju-
vant alum is a strong inducer of Th2 responses (Baz et al.
2012), only the IgG1 class-switched cells were measured.
Within this gated population, memory cells were defined as
CD19+IgD−GPI/NP+IgG1+CD38+. Analysis of activated B
cells that were specific for antigen was defined as
CD19+IgD−GPI/NP+. Gating strategies and representative
flow plots are outlined in Suppl. Fig. 1. Fluorescence Minus
One (FMO) controls were included to allow accurate gating.
Sample analysis was performed on a FortessaX20 flow
cytometer and Cell Quest software packages (BD
Biosciences, USA). A minimum of 500,000 events was ac-
quired. Data were analysed using FlowJo Version 9.9.6 soft-
ware (TreeStar).
ELISPOTs
In vitro differentiation of antibody-secreting cells (ASCs) was
performed using ELISPOT, as previously described (Zotos
1988 Parasitol Res (2019) 118:1987–1992
et al. 2010), and visualised using the BCIP/NBTsystem (KPL,
USA). Coating concentrations for NP-BSA and GPI-BSA
were optimised at 10 μg/mL.
Statistical analysis
Statistical analysis included comparingmean values byMann-
Whitney using Prism version 7 software (GraphPad).
Statistical significance comparing more than two groups in
an analysis was determined using Kruskal-Wallis followed
by Dunn’s multiple comparison test as indicated. Statistical
analysis included comparisons with the untreated and treated
naïve groups.
Results and discussion
The malaria murine model is a crucial biological tool for un-
derstanding host and pathogen interactions. Furthermore, anti-
malarial treatment is warranted to ensure mice do not succumb
to Plasmodium infection yet there is limited data on the effect
of these drugs on mounting effective immune responses ad-
ministered at this timepoint. We wanted to investigate if
administration of these drugs, using the widely accepted stan-
dard protocol for clearing Plasmodium parasites, had an effect
on antigen-specific B cell responses in the murine model.
GPI is an important malaria glycolipid with a role in ma-
laria pathogenesis (Schofield and Hackett 1993) and NP is a
commonly used antigen to study various aspects of B cell
responses (Inamine et al. 2005; Lalor et al. 1992). To measure
the B cell priming response and ensuing proliferation follow-
ing first encounter with foreign GPI-KLH or NP-KLH anti-
gen, mice were euthanised and splenocytes isolated at day 14
post-immunisation. Day 14was chosen to ensure the detection
of a high number of antigen-specific B cells.
Immunisation with either NP-KLH or GPI-KLH in the ab-
sence of CQ/Pyr treatment induced significant B cell prolifer-
ation by day 14 as expected (Fig. 1). Mean B cell counts per
spleen in these immunised untreated groups were significantly
higher than those in naïve mice (CQ/Pyr treated and untreated)
for GPI+/NP+ B cell counts, GPI+/NP+IgG1+ B cell counts,
GC B cell counts, and GPI+/NP+IgG1+ memory B cell (MBC)
counts (Fig. 1a–d). Although overall GC cells were readily
detectable, the low numbers of GC cells in naïve mice (CQ/
Pyr treated and untreated) presented in Fig. 1c represent only
activated GC cells as inactivated IgD− B cells were removed
Fig. 1 At day 14, CQ/Pyr treatment suppressed NP+ MBCs in NP-KLH-
immunised mice. Mice were vaccinated at D0 with NP-KLH (n = 16) or
GPI-KLH (n = 16). Naïve mice (n = 16) were included as a baseline. At
D5, half the mice in each group were treated with CQ/Pyr (open squares).
The remaining mice received no treatment (filled circles). Activated B
cell populations were analysed at day 14 by flow cytometry and the
number of cells per spleen for (A) antigen (Ag)-specific B cells, (B)
antigen (Ag)-specific IgG1 B cells, (C) germinal centre (GC) B cells,
and (D) antigen (Ag)-specific IgG1 memory B cells was determined.
Additionally, the frequency (%) of antigen (Ag)-specific IgG1 MBCs as
a proportion of all antigen-specific IgG1 B cells was assessed (E).
Figure is a representative of 2 independent experiments. Statistical
analysis was performed using the non-parametric Kruskal-Wallis test
and significance determined using Dunn’s multiple comparison.
Comparing CQ/Pyr treatment vs. no CQ/Pyr was analysed using the
non-parametric unpaired Mann-Whitney test. Data are represented as
mean ± SEM. *P < 0.05
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from the analysis by gating (Supp. Fig. 1). CQ/Pyr treatment
induced a significant suppression of frequency of NP+IgG1+
MBCs in NP-KLH-immunised mice compared with untreated
NP-KLH-immunised mice (Fig. 1e). Although at this
timepoint there were no other significant differences between
treatment and no treatment, CQ/Pyr appeared to have a subtle
effect as few B cell parameters were no longer significantly
different to naïve mice (Fig. 1a–d). For the GPI-KLH-
immunised drug-treated mice, although the mean GPI+ B cell
count was significantly higher than that for naïve drug-treated
mice, it was not significantly higher than that for naïve un-
treated mice (Fig. 1a). For the NP-KLH-immunised drug-
treated mice, this subtle suppressive effect was observed for
NP+-specific B cells (Fig. 1a), GC counts (Fig. 1c), andMBCs
(Fig. 1d and e). Here, NP-KLH-immunised treated mice did
not have significantly higher mean cell counts nor MBC fre-
quencies than naïve mice (CQ/Pyr treated and untreated). This
pattern observed for GPI-KLH- and NP-KLH-immunised
drug-treated mice was also extended to frequencies of GPI+/
NP+ or GPI+/NP+IgG1+ B cells (Supp. Fig. 2a and b).
Based on these findings, we wanted to further investigate if
the significant suppression of the frequency of NP-specific
MBCs resolved and if the CQ/Pyr effect was reversible upon
a secondary boost with antigen. By day 28, suppression of B
cell proliferation in CQ/Pyr-treatedNP-KLH-immunisedmice
resolved, with B cell counts now significantly higher com-
pared with naïve mice (CQ/Pyr treated and untreated) for most
B cell subtypes (Fig. 2a–d) and no significant differences in
MBC frequencies between CQ/Pyr-treated and untreated NP-
KLH-immunised mice (Fig. 2d). The resolution of
Fig. 2 B cell suppression resolves in CQ/Pyr-treated mice. Mice were
vaccinated at D0 with NP-KLH (n = 18) or GPI-KLH (n = 17). Naïve
mice (n = 18) were included as a baseline. At D5, mice were either treated
with CQ/Pyr (open squares) or left untreated (filled circles). At day 16,
NP-KLH and GPI-KLH mice were boosted with 20 μg. Mice were
euthanised at day 28 and activated B cell populations were analysed by
flow cytometry and the number of cells per spleen for (A) antigen-specific
B cells, (B) antigen-specific IgG1 B cells, and (C) antigen-specific IgG1
MBCs was determined at day 28. Additionally, the frequency (%) of
antigen-specific IgG1 MBCs as a proportion of all antigen-specific
IgG1 B cells was calculated (E). All graphs are representative of 2 inde-
pendent experiments. Statistical analysis was performed using the non-
parametric Kruskal-Wallis test and significance determined using Dunn’s
multiple comparison. Comparing CQ/Pyr treatment vs. no CQ/Pyr was
analysed using the non-parametric unpaired Mann-Whitney test. Data are
represented as mean ± SEM. *P < 0.05
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suppression was also observed for the frequencies of antigen
specific and antigen-specific IgG1 B cells for both GPI-KLH-
and NP-KLH-immunised mice (see Supp. Fig. 3). Similarly,
there were no differences between CQ/Pyr-treated and un-
treated GPI-KLH-immunised mice for all B cell parameters
(Fig. 2a–d). CQ/Pyr-treated GPI-KLH-immunised mice had
lower cellular counts of MBCs that were not significantly
different to naïve mice (CQ/Pyr treated and untreated).
However, the proportion of MBCs of total GPI-specific
IgG1 B cells was significantly higher than the proportion of
MBCs in naïve mice (CQ/Pyr treated and untreated) (Fig. 2d).
Whether this slight low count of GPI+ MBCs in CQ/Pyr-
treated GPI-KLH-immunised mice increased at a later
timepoint was not assessed in the current study.
Finally, we wanted to establish if CQ/Pyr treatment impaired
the production of functional antigen-specific antibody-secreting
cells (ASCs) from the spleen at day 28. CQ/Pyr did not affect the
production of anti-GPI IgG1+ ASCs nor anti-NP IgG1+ ASCs
(Fig. 3). Interestingly, there was a significant difference between
CQ/Pyr-treated and untreated NP-KLH-immunised mice as a
significantly lower count of anti-NP IgG1+ ASCs was observed
in untreated mice (Fig. 3). As this study chose only one late
timepoint, it was not ascertained if the peak of ASCs produced
in the spleen occurred earlier in these untreated mice, which
could explain the lower count observed.
Our findings are highly suggestive of CQ/Pyr modulating
antigen-specific B cell responses when administered
according to standard protocols, that is, at day 5 post infection
to avoid fatalities due to high parasitaemia (Schofield et al.
2017). This modulation is reflected at day 14with a significant
suppression of the frequency of NP-specific MBCs.
Furthermore, although not significant, CQ/Pyr-treated NP-
or GPI-immunised mice had lower B cell counts that affected
their statistical difference to the naïve populations (CQ/Pyr
treated and untreated). By day 28, the observed early signifi-
cant suppression of NP+ MBCs was resolved, as were most of
the other B cell counts, suggestive of a transient effect of CQ/
Pyr. The current study cannot conclusively ascertain why the
effect of CQ/Pyr treatment differed between NP- and GPI-
immunised mice. Both NP and GPI were conjugated to
KLH to elicit protein T–dependent responses (Swaminathan
et al. 2014) and received the same concentration of antigen
administered in alum. It is unlikely to be due to potential
differences in CQ/Pyr suppression of KLH T cell priming, as
T cell priming has been shown to initiate within 8–20 h post
vaccination and peak around days 5 to 7 (Mempel et al. 2004),
thus occurring prior to drug treatment. Therefore, differences
in immunogenicity observed may be due to antigenic size
(NP-KLH is far larger than GPI-KLH) or, conceivably, differ-
ences in conjugation efficiencies. Further studies will be re-
quired to properly address the underlying mechanism behind
the observed differences.
Resolution of cellular suppression by CQ/Pyr is consis-
tent with other studies that have shown that the anti-
malarial drugs delay humoral responses to chikungunya
virus (Roques et al. 2018) and that withdrawal of CQ
reverses suppressed humoral responses in rheumatoid ar-
thritis patients (Brauner et al. 2017). Consequently, this
research also raises crucial questions concerning not only
mounting effective immunity against Plasmodium sp.
whilst taking malaria prophylaxis but also the efficacy of
co-administered vaccines including the malaria vaccine
RTS,S. This avenue of research requires further investiga-
tion, as does exploring if T cell responses are suppressed
by CQ/Pyr treatment using this same model.
Although our study was not designed to ascertain the exact
modulation of kinetic effects of CQ/Pyr on B cells, nor the
direct effect of antigen activation with simultaneous
immunisation and drug treatment, our observations clearly
showed that the standard CQ/Pyr treatment protocol of para-
site clearance in mice effects B cells. This suggests that drug-
treated controls are worthwhile to include in any immune-
related measurement when using this drug treatment regimen
to account for the effect of CQ/Pyr on immune cells.
Acknowledgements The authors would like to thank Dr. Kim Jacobson
for her invaluable input regarding the NP-KLH immunisation model. We
would like to thank Carolina Alvarado for assistance with animal proce-
dures and the Bundoora Antibody facility for generating IgD-A680 and
Gr-A680.
Fig. 3 CQ/Pyr did not suppress numbers of antigen-specific IgG1
antibody-secreting cells (ASCs). Mice were vaccinated at D0 with NP-
KLH (n = 18) or GPI-KLH (n = 17). Naïvemice (n = 18) were included as
a baseline. At D5, mice were either treated with CQ/Pyr (open squares) or
left untreated (filled circles). At day 16, NP-KLH and GPI-KLH mice
were boosted with 20 μg. Mice were euthanised at day 28. Splenocytes
were plated onto pre-coated ELISPOTs to measure numbers of ASCs.
Graph is representative of combined data obtained from 2 independent
experiments. Comparing CQ/Pyr treatment vs. no CQ/Pyr was analysed
using the non-parametric unpaired Mann-Whitney test. Data are repre-
sented as mean ± SEM. *P < 0.05
Parasitol Res (2019) 118:1987–1992 1991
Author’s contributions H.J. authored the manuscript. L.S. and H.J. pro-
vided the conceptual framework for the study. H.J., E.E. and L.S. de-
signed the experiments and H.J. performed all experiments. E.E. provided
critical support for flow cytometry data analysis. L.S. and E.E. critically
reviewed the manuscript.
Funding Dr. Joseph was supported by the NHMRC Peter Doherty
Fellowship (GNT1052580). This research was funded by the NHMRC
(GNT1093311) and the Bill and Melinda Gates Foundation
(OPP1136441).
Compliance with ethical standards Inbred male and female
C57BL/6 mice (6–8 weeks of age) were used for all experiments and
protocols complied with the Walter and Eliza Hall Institute Animal
Ethics Committee requirements.
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM,
Hamelin ME, Mallett C, Papadopoulou B, Boivin G (2012) Effects
of different adjuvants in the context of intramuscular and intranasal
routes on humoral and cellular immune responses induced by
detergent-split A/H3N2 influenza vaccines in mice. Clinical and
Vaccine Immunology: CVI 19(2):209–218. https://doi.org/10.
1128/CVI.05441-11
Brauner S, Folkersen L, KvarnströmM, Meisgen S, Petersen S, Franzén-
Malmros M, Mofors J, Brokstad KA, Klareskog L, Jonsson R,
Westerberg LS, Trollmo C, Malmström V, Ambrosi A, Kuchroo
VK, Nordmark G, Wahren-Herlenius M (2017) H1N1 vaccination
in Sjogren’s syndrome triggers polyclonal B cell activation and pro-
motes autoantibody production. Ann Rheum Dis 76(10):1755–
1763. https://doi.org/10.1136/annrheumdis-2016-210509
Frosch AEP, John CC (2012) Immunomodulation in Plasmodium
falciparum malaria: experiments in nature and their conflicting im-
plications for potential therapeutic agents. Expert Rev Anti-Infect
Ther 10:1343–1356
Helegbe GK, Huy NT, Yanagi T, Shuaibu MN, Kikuchi M, Cherif MS,
Hirayama K (2018) Elevated IL-17 levels in semi-immune anaemic
mice infected with Plasmodium berghei ANKA. Malar J 17(1):169.
https://doi.org/10.1186/s12936-018-2257-x
Inamine A, Takahashi Y, Baba N, Miyake K, Tokuhisa T, Takemori T,
Abe R (2005) Two waves of memory B-cell generation in the pri-
mary immune response. Int Immunol 17(5):581–589. https://doi.
org/10.1093/intimm/dxh241
Jeffery GM (1966) Epidemiological significance of repeated infections
with homologous and heterologous strains and species of
Plasmodium. Bull World Health Organ 35:873–882
Khan MW, Saadalla A, Ewida AH, al-Katranji K, al-Saoudi G, Giaccone
ZT, Gounari F, Zhang M, Frank DA, Khazaie K (2018) The STAT3
inhibitor pyrimethamine displays anti-cancer and immune stimula-
tory effects in murine models of breast cancer. Cancer Immunology,
Immunotherapy : CII 67(1):13–23. https://doi.org/10.1007/s00262-
017-2057-0
Lalor PA, Nossal GJ, Sanderson RD, McHeyzer-Williams MG (1992)
Functional and molecular characterization of single, (4-hydroxy-3-
nitrophenyl) acetyl (NP)-specific, IgG1+ B cells from antibody-
secreting and memory B cell pathways in the C57BL/6 immune
response to NP. Eur J Immunol 22:3001–3011
Lau LS, Fernandez-Ruiz D, Mollard V, Sturm A, Neller MA, Cozijnsen
A, Gregory JL, Davey GM, Jones CM, Lin YH, Haque A,
Engwerda CR, Nie CQ, Hansen DS, Murphy KM, Papenfuss AT,
Miles JJ, Burrows SR, de Koning-Ward T, McFadden GI, Carbone
FR, Crabb BS, Heath WR (2014) CD8+ T cells from a novel T cell
receptor transgenic mouse induce liver-stage immunity that can be
boosted by blood-stage infection in rodent malaria. PLoS Pathog 10:
e1004135
Lee MP, Tanabe O, Shi L, Jearawiriyapaisarn N, Lucas D, Engel JD
(2017) The orphan nuclear receptor TR4 regulates erythroid cell
proliferation and maturation. Blood. 130:2537–2547
Mempel TR, Henrickson SE, Von Andrian UH (2004) T-cell priming by
dendritic cells in lymph nodes occurs in three distinct phases. Nature
427(6970):154–159. https://doi.org/10.1038/nature02238
Qin X, Chen G, Feng Y, Zhu X, du Y, Pang W, Qi Z, Cao Y (2014) Early
treatment with chloroquine inhibits the immune response against
Plasmodium yoelii infection in mice. Tohoku J Exp Med 234(4):
271–280
Roques P, Thiberville SD, Dupuis-Maguiraga L, Lum FM, Labadie K,
Martinon F, Gras G, Lebon P, Ng L, de Lamballerie X, le Grand R
(2018) Paradoxical effect of chloroquine treatment in enhancing
chikungunya virus infection. Viruses 10(5). https://doi.org/10.
3390/v10050268
Ryg-Cornejo V, Ioannidis LJ, Ly A, Chiu CY, Tellier J, Hill DL, Preston
SP, Pellegrini M, Yu D, Nutt SL, Kallies A, Hansen DS (2016a)
Severe malaria infections impair germinal center responses by
inhibiting T follicular helper cell differentiation. Cell Rep 14:68–81
Ryg-Cornejo V, Ly A, Hansen DS (2016b) Immunological processes
underlying the slow acquisition of humoral immunity to malaria.
Parasitology. 143:199–207
Rynes RI (1997) Antimalarial drugs in the treatment of rheumatological
diseases. Br J Rheumatol 36(7):799–805
Schofield L, Hackett F (1993) Signal transduction in host cells by a
glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med
177:145–153
Schofield L, Ioannidis LJ, Karl S, Robinson LJ, Tan QY, Poole DP,
Betuela I, Hill DL, Siba PM, Hansen DS, Mueller I, Eriksson EM
(2017) Synergistic effect of IL-12 and IL-18 induces TIM3 regula-
tion of gammadelta T cell function and decreases the risk of clinical
malaria in children living in Papua New Guinea. BMC Med 15:114
Swaminathan A, Lucas RM, Dear K, McMichael AJ (2014) Keyhole
l impe t haemocyan in - a mode l an t i gen fo r human
immunotoxicological studies. Br J Clin Pharmacol 78(5):1135–
1142. https://doi.org/10.1111/bcp.12422
Zotos D, Coquet JM, Zhang Y, Light A, D'Costa K, Kallies A, Corcoran
LM, Godfrey DI, Toellner KM, Smyth MJ, Nutt SL, Tarlinton DM
(2010) IL-21 regulates germinal center B cell differentiation and
proliferation through a B cell-intrinsic mechanism. J Exp Med
207:365–378
Publisher’s note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
1992 Parasitol Res (2019) 118:1987–1992
